| Elizabeth A Egan, MD | |
|
2301 E Evesham Rd Ste 110, Voorhees, NJ 08043-4502 | |
| (856) 772-1600 | |
| (856) 772-9031 |
| Full Name | Elizabeth A Egan |
|---|---|
| Gender | Female |
| Speciality | Gastroenterology |
| Experience | 24 Years |
| Location | 2301 E Evesham Rd Ste 110, Voorhees, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174685416 | NPI | - | NPPES |
| 0137448 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 25MA08279700 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virtua West Jersey Hospitals | Voorhees, NJ | Hospital |
| Virtua Our Lady Of Lourdes Hospital | Camden, NJ | Hospital |
| Penn Presbyterian Medical Center | Philadelphia, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virtua Medical Group, Pa | 9830222397 | 1226 |
News Archive
Lancet Neurology, a prestigious journal in its domain, publishes in its last issue, an article entitled "Pitolisant versus placebo and modafinil in patients with narcolepsy: a double-blind randomised trial" authored by Y. Dauvilliers and others from the HARMONY I study group which proposes a novel treatment for this orphan disease. It is accompanied by a Commentary entitled "A need for new treatments in narcolepsy".
Readmission penalties against hospitals providing care to socioeconomically disadvantaged patients have dropped 14 percentage points under new rules adopted in 2019 that more equitably account for low-income populations being served, according to a new analysis led by UT Southwestern Medical Center and Harvard researchers.
Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).
Type 2 diabetes patients, who face higher risk of cardiovascular disease, often take a combination of medications designed to lower their LDL or "bad" cholesterol and triglyceride levels while raising their HDL or "good" cholesterol because doctors long have thought that taken together, the drugs offer protection from heart attacks and improve survival.
Receptos, a drug discovery and development company, announced today the establishment of a collaboration with Eli Lilly and Company to research and develop small molecule modulators of an undisclosed GPCR target.
› Verified 4 days ago
| Entity Name | Virtua Medical Group, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226515 PECOS PAC ID: 9830222397 Enrollment ID: O20100804000338 |
News Archive
Lancet Neurology, a prestigious journal in its domain, publishes in its last issue, an article entitled "Pitolisant versus placebo and modafinil in patients with narcolepsy: a double-blind randomised trial" authored by Y. Dauvilliers and others from the HARMONY I study group which proposes a novel treatment for this orphan disease. It is accompanied by a Commentary entitled "A need for new treatments in narcolepsy".
Readmission penalties against hospitals providing care to socioeconomically disadvantaged patients have dropped 14 percentage points under new rules adopted in 2019 that more equitably account for low-income populations being served, according to a new analysis led by UT Southwestern Medical Center and Harvard researchers.
Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).
Type 2 diabetes patients, who face higher risk of cardiovascular disease, often take a combination of medications designed to lower their LDL or "bad" cholesterol and triglyceride levels while raising their HDL or "good" cholesterol because doctors long have thought that taken together, the drugs offer protection from heart attacks and improve survival.
Receptos, a drug discovery and development company, announced today the establishment of a collaboration with Eli Lilly and Company to research and develop small molecule modulators of an undisclosed GPCR target.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth A Egan, MD 301 Lippincott Dr Ste 410, Marlton, NJ 08053-4197 Ph: (856) 355-0340 | Elizabeth A Egan, MD 2301 E Evesham Rd Ste 110, Voorhees, NJ 08043-4502 Ph: (856) 772-1600 |
News Archive
Lancet Neurology, a prestigious journal in its domain, publishes in its last issue, an article entitled "Pitolisant versus placebo and modafinil in patients with narcolepsy: a double-blind randomised trial" authored by Y. Dauvilliers and others from the HARMONY I study group which proposes a novel treatment for this orphan disease. It is accompanied by a Commentary entitled "A need for new treatments in narcolepsy".
Readmission penalties against hospitals providing care to socioeconomically disadvantaged patients have dropped 14 percentage points under new rules adopted in 2019 that more equitably account for low-income populations being served, according to a new analysis led by UT Southwestern Medical Center and Harvard researchers.
Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).
Type 2 diabetes patients, who face higher risk of cardiovascular disease, often take a combination of medications designed to lower their LDL or "bad" cholesterol and triglyceride levels while raising their HDL or "good" cholesterol because doctors long have thought that taken together, the drugs offer protection from heart attacks and improve survival.
Receptos, a drug discovery and development company, announced today the establishment of a collaboration with Eli Lilly and Company to research and develop small molecule modulators of an undisclosed GPCR target.
› Verified 4 days ago
Kumar Rajagopalan, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 900 Centennial Blvd Ste M, Voorhees, NJ 08043 Phone: 856-325-6750 Fax: 856-325-6777 | |
Amy M Evangelisto, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2301 E. Evesham Road, Bldg 800, Suite 115, Voorhees, NJ 08043 Phone: 856-424-5005 Fax: 856-424-4716 | |
Stephen M Akers, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 900 Centennial Blvd, Suite K, Voorhees, NJ 08043 Phone: 856-325-6789 | |
Jason Palermo, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2309 E Evesham Rd, Suites 201 & 202, Voorhees, NJ 08043 Phone: 856-325-5400 Fax: 856-325-5416 | |
Dr. Robert Charles Baker, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 75 Wynnewood Dr, Voorhees, NJ 08043 Phone: 609-352-2012 Fax: 856-489-1420 | |
Dr. Eduardo Francisco Enriquez, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3 Brendenwood Dr, Voorhees, NJ 08043 Phone: 856-874-0202 Fax: 856-874-0220 | |
Arielle S. Silver, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2301 E. Evesham Road, Bldg 800, Suite 115, Voorhees, NJ 08043 Phone: 856-424-5005 Fax: 856-424-4716 |